Efficacy of imiquimod cream, 5%,for lentigo maligna after complete excision: A study of 43 patients

Archives of Dermatology

Volumn 147, Issue 10, 2011, Pages 1191-1195

  Ly, Lena ^a   Kelly, John William ^a,b   O'Keefe, Rodney ^d   Sutton, Tina ^a,e   Dowling, John P ^a,b   Swain, Sarah ^a,b,f   Byrne, Marguerite ^a   Curr, Nathan ^a,g   Wolfe, Rory ^c   Chamberlain, Alex ^a   Haskett, Martin ^a  

^a The Alfred   (Australia)

^b Department of Medicine ^*  (Australia)

^c MONASH UNIVERSITY   (Australia)

^d Dermpath Pty Ltd   (Australia)

^e SKIN AND CANCER FOUNDATION   (Australia)

^f PETER MACCALLUM CANCER CENTRE   (Australia)

^g Fremantle Hospital and Health Service   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

IMIQUIMOD; PARACETAMOL; PETROLATUM;

ARTICLE; BASAL CELL CARCINOMA; CARBON DIOXIDE LASER; COMBINATION CHEMOTHERAPY; CREAM; CRYOTHERAPY; DRUG EFFICACY; DRUG TOLERABILITY; HISTOPATHOLOGY; HUMAN; INTERVENTION STUDY; MALIGNANT LENTIGO; MICROSCOPY; MONOTHERAPY; OPEN STUDY; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PRIORITY JOURNAL; REST; SENSITIVITY AND SPECIFICITY; SKIN DISEASE; SKIN INFLAMMATION; SKIN SURGERY; TREATMENT DURATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMINOQUINOLINES; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; EMOLLIENTS; FEMALE; HUMANS; HUTCHINSON'S MELANOTIC FRECKLE; MALE; MIDDLE AGED; SKIN NEOPLASMS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 80054751332     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archdermatol.2011.260     Document Type: Article

References (45)

1. Buettiker UV, Yawalkar NY, Braathen LR, Hunger RE. Imiquimod treatment of lentigo maligna: an open-label study of 34 primary lesions in 32 patients. Arch Dermatol. 2008;144(7):943-945. (Pubitemid 352039751)
2. Cotter MA, McKenna JK, Bowen GM. Treatment of lentigo maligna with imiquimod before staged excision. Dermatol Surg. 2008;34(2):147-151.
3. de Troya-Martín M, Frieyro-Elicegui M, Fúnez Liébana R, Aguilar Bernier M, Fernández-Canedo NI, Blázquez Sánchez N. Lentigo maligna managed with topical imiquimod and dermoscopy: report of two cases. Dermatol Surg. 2008;34(11): 1561-1566.
4. Fleming CJ, Bryden AM, Evans A, Dawe RS, Ibbotson SH. A pilot study of treatment of lentigo maligna with 5% imiquimod cream. Br J Dermatol. 2004;151(2):485-488. (Pubitemid 39215164)
5. Kupfer-Bessaguet I, Guillet G, Misery L, Carre JL, Leroy JP, Sassolas B. Topical imiquimod treatment of lentigo maligna: clinical and histologic evaluation. J Am Acad Dermatol. 2004;51(4):635-639. (Pubitemid 39278087)
6. Mahoney M-H, Joseph MG, Temple C. Topical imiquimod therapy for lentigo maligna. Ann Plast Surg. 2008;61(4):419-424.
7. Micali G, Lacarrubba F, Nardone B, Nasca MR. Videodermatoscopy of lentigo maligna treated with imiquimod. J Drugs Dermatol. 2008;7(11):1077-1080.
8. Naylor MF, Crowson N, Kuwahara R, et al. Treatment of lentigo maligna with topical imiquimod. Br J Dermatol. 2003;149(suppl 66):66-70.
9. Powell AM, Robson AM, Russell-Jones R, Barlow RJ. Imiquimod and lentigo maligna: a search for prognostic features in a clinicopathological study with longterm follow-up. Br J Dermatol. 2009;160(5):994-998.
10. Powell AM, Russell-Jones R, Barlow RJ. Topical imiquimod immunotherapy in the management of lentigo maligna. Clin Exp Dermatol. 2004;29(1):15-21. (Pubitemid 38183642)
11. Spenny ML, Walford J, Werchniak AE, et al. Lentigo maligna (melanoma in situ) treated with imiquimod cream 5%: 12 case reports. Cutis. 2007;79(2):149-152.
12. Wolf IH, Cerroni L, Kodama K, Kerl H. Treatment of lentigo maligna (melanoma in situ) with the immune response modifier imiquimod. Arch Dermatol. 2005;141(4):510-514. (Pubitemid 40547412)
13. Ackerman AB, Niven J, Grant-Kels JM. Differential Diagnosis in Dermatopathology. Philadelphia, PA: Lea & Febiger; 1982.
14. Farmer ER, Gonin R, Hanna MP. Discordance in the histopathologic diagnosis of melanoma and melanocytic nevi between expert pathologists. Hum Pathol. 1996;27(6):528-531. (Pubitemid 26187274)
15. Florell SR, Boucher KM, Leachman SA, et al. Histopathologic recognition of involved margins of lentigo maligna excised by staged excision: an interobserver comparison study. Arch Dermatol. 2003;139(5):595-604. (Pubitemid 36576375)
16. Agarwal-Antal N, Bowen GM, Gerwels JW. Histologic evaluation of lentigo maligna with permanent sections: implications regarding current guidelines. J Am Acad Dermatol. 2002;47(5):743-748. (Pubitemid 35239337)
17. Osborne JE, Hutchinson PE. A follow-up study to investigate the efficacy of initial treatment of lentigo maligna with surgical excision. Br J Plast Surg. 2002;55(8):611-615. (Pubitemid 35469781)
18. Ng JC, Swain S, Dowling JP, Wolfe R, Simpson P, Kelly JW. The impact of partial biopsy on histopathologic diagnosis of cutaneous melanoma: experience of an Australian tertiary referral service. Arch Dermatol. 2010;146(3):234-239.
19. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33(1):159-174. (Pubitemid 8054849)
20. Bosbous MW, Dzwierzynski WW, Neuburg M. Staged excision of lentigo maligna and lentigomaligna melanoma: a 10-year experience. Plast Reconstr Surg. 2009;124(6):1947-1955.
21. Van Meurs T, Van Doorn R, Kirtschig G. Treatment of lentigo maligna with imiquimod cream: a long-term follow-up study of 10 patients. Dermatol Surg. 2010;36(6):853-858.
22. Ahmed I, Berth-Jones J. Imiquimod: a novel treatment for lentigo maligna. Br J Dermatol. 2000;143(4):843-845.
23. Bassukas ID, Gamvroulia C, Zioga A, Nomikos K, Fotika C. Cryosurgery during topical imiquimod: a successful combination modality for lentigo maligna. Int J Dermatol. 2008;47(5):519-521. (Pubitemid 351560323)
24. Borucki U, Metze D. Topical treatment of lentigo maligna melanoma with imiquimod 5% cream. Dermatology. 2003;207(3):326-328. (Pubitemid 37329209)
25. Bourguignon R, Paquet P, Quatresooz P, Piérard GE. How I treat . . . lentigo maligna by topical imiquimod [in French]. Rev Med Liege. 2005;60(9):691-694. (Pubitemid 41436258)
26. Chapman MS, Spencer SK, Brennick JB. Histologic resolution of melanoma in situ (lentigo maligna) with 5% imiquimod cream. Arch Dermatol. 2003;139(7):943-944. (Pubitemid 36898941)
27. Curiel-Lewandrowski C, Williams CM, Swindells KJ, et al. Use of in vivo confocal microscopy in malignant melanoma: an aid in diagnosis and assessment of surgical and nonsurgical therapeutic approaches. Arch Dermatol. 2004;140(9):1127-1132. (Pubitemid 39223121)
28. du Plessis PJ. Lentigo maligna successfully treated with imiquimod. S Afr J Surg. 2007;45(2):72.
29. Epstein E. Extensive lentigo maligna clearing with topical imiquimod. Arch Dermatol. 2003;139(7):944-945. (Pubitemid 36898942)
30. Fisher GH, Lang PG. Treatment of melanoma in situ on sun-damaged skin with topical 5% imiquimod cream complicated by the development of invasive disease. Arch Dermatol. 2003;139(7):945-947. (Pubitemid 36898943)
31. Hopson B, Richey D, Sajben FP. Treatment of lentigo maligna with imiquimod 5% cream. J Drugs Dermatol. 2007;6(10):1037-1040.
32. Kamin A, Eigentler TK, Radny P, Bauer J, Weide B, Garbe C. Imiquimod in the treatment of extensive recurrent lentigo maligna. J Am Acad Dermatol. 2005;52(2)(suppl 1):51-52.
33. Martín T, Ojeda A, Martínez S, Vera Á. Lentigo maligna treated with 5% imiquimod cream [in Spanish]. Actas Dermosifiliogr. 2005;96(10):700-702. (Pubitemid 43362580)
34. Michalopoulos P, Yawalkar N, Brönnimann M, Kappeler A, Braathen LR. Characterization of the cellular infiltrate during successful topical treatment of lentigo maligna with imiquimod. Br J Dermatol. 2004;151(4):903-906. (Pubitemid 39482129)
35. Muñoz CM, Sánchez JL, Martín-García RF. Successful treatment of persistent melanoma in situ with 5% imiquimod cream. Dermatol Surg. 2004;30(12, pt 2):1543-1545. (Pubitemid 40053522)
36. Noel B, Kunzle N. Image in clinical medicine: lentigo maligna. N Engl J Med. 2005;353(20):2176.
37. Piazza CD, Sampaio SAP. Remission of extensive lentigo maligna after treatment with imiquimod [in English and Portuguese]. An Bras Dermatol. 2009;84(1):82-84.
38. Powell A-M, Russell-Jones R. Amelanotic lentigo maligna managed with topical imiquimod as immunotherapy. J Am Acad Dermatol. 2004;50(5):792-796. (Pubitemid 38580565)
39. Ramsdell AM, Zeitouni N. Long-term follow-up of a hemifacial lentigo maligna treated using 5% imiquimod. Dermatol Surg. 2009;35(2):287-290.
40. van Meurs T, van Doorn R, Kirtschig G. Recurrence of lentigo maligna after initial complete response to treatment with 5% imiquimod cream. Dermatol Surg. 2007;33(5):623-627.
41. Woodmansee CS, McCall MW. Recurrence of lentigo maligna and development of invasive melanoma after treatment of lentigo maligna with imiquimod. Dermatol Surg. 2009;35(8):1286-1289.
42. Barlow JO, Maize J Sr, Lang PG. The density and distribution of melanocytes adjacent to melanoma and nonmelanoma skin cancers. Dermatol Surg. 2007;33(2):199-207. (Pubitemid 46208113)
43. Beltraminelli H, Shabrawi-Caelen LE, Kerl H, Cerroni L. Melan-A - positive "pseudomelanocytic nests": a pitfall in the histopathologic and immunohistochemical diagnosis of pigmented lesions on sun-damaged skin. Am J Dermatopathol. 2009;31(3):305-308.
44. El Shabrawi-Caelen L, Kerl H, Cerroni L. Melan-A: not a helpful marker in distinction between melanoma in situ on sun-damaged skin and pigmented actinic keratosis. Am J Dermatopathol. 2004;26(5):364-366. (Pubitemid 39287355)
45. Zalaudek I, Horn M, Richtig E, Hödl S, Kerl H, Smolle J. Local recurrence in melanoma in situ: influence of sex, age, site of involvement and therapeutic modalities. Br J Dermatol. 2003;148(4):703-708. (Pubitemid 36629748)